Active	Status	Sponsor type	Region	Phase	Filter
13 Active 10 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sherman, Scott E
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
Richards, Scott
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24
Callan, Michael
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies	Completed	2	130	US	CT1812	Cognition Therapeutics, National Institute on Aging (NIA)	Dementia with Lewy Bodies	11/24	11/24